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 Glioblastoma—The  Clinical 
Challenge
    Gliomas are the most common primary 
tumors of the brain, with an incidence 
of about 25,000 new cases per year in 
the United States [1]. At least half of all 
gliomas exhibit aggressive, malignant 
behavior. Glioblastoma multiforme 
(GBM), in particular, is clinically and 
pathologically malignant [1–3]. Patients 
with GBM have a poor prognosis, with 
a median survival of one year with 
aggressive therapy; fewer than 5% will 
survive ﬁ  ve years [1,4,5]. In spite of its 
seemingly low incidence, mortality from 
GBM accounts for 3%–4% of all cancer 
deaths each year in the US [1]. 
    The mainstays of treatment include 
surgical resection, radiation, and 
chemotherapy. Once adjuvant therapy 
is completed, gliomas generally recur 
at the surgical resection margin(s), and 
tend to be more aggressive than at initial 
presentation (Figure 1). At this stage 
in the course of disease, most therapy 
is palliative [1–5]. With the exception 
of a few early-stage clinical trials, 
current antiglioma therapies have not 
yet taken advantage of speciﬁ  c genetic 
abnormalities that lead to and sustain 
cancer. A new study by Alexander 
Levitzki and colleagues in this issue 
of   PLoS Medicine   presents promising 
preclinical results that appear to do 
just this, using a novel ligand-directed 
method to deliver double-stranded RNA 
molecules to cancer cells [6].
    Pathologic and Molecular Features
    Gliomas are primary brain tumors that 
display pathological and ultrastructural 
features of glial cell differentiation. 
Primary brain tumors are classiﬁ  ed 
on the basis of presumed line of 
neuroepithelial differentiation: 
astrocytic, oligodendroglial, and 
ependymal (Figure 1). Astrocytomas 
predominate, making up 80%–85% 
of all glial neoplasms, and will be the 
focus of this Perspective. 
    Grading is performed on a scale, 
from low to high, according to a 
tumor’s histological features (Figure 1; 
Table 1). World Health Organization 
grade IV tumors, the GBMs, are 
aggressive, invasive, destructive 
malignancies, with increased mitotic 
activity, pronounced angiogenesis, 
necrosis, and proliferation rates two to 
ﬁ  ve times higher than grade III tumors 
[2]. Roughly 50% of all GBMs are 
primary or de novo in origin, while the 
other half arises secondarily from lower-
grade tumors [2], often after some 
years of latency [2]. Current models 
of gliomagenesis coincide with the two 
clinically recognized forms of GBM, de 
novo and progressive (Figure 1).
    Most de novo GBMs do not have 
alterations in   TP53  ; rather, nearly 
all carry EGF receptor   (EGFR)   gene 
ampliﬁ  cations, often combined with 
gene rearrangements that lead to a 
constitutively active, truncated receptor. 
By contrast, progression from a low-
grade to a high-grade glioma often 
involves the serial accumulation of 
genetic alterations that inactivate tumor 
suppressor genes—such as   TP53, p16, 
RB, PTEN  —or activate oncogenes such 
as   MDM2, CDK4   and   CDK6   [2–4]. 
Functionally, gliomas seem to arise along 
two competing paths [3–5,7]. The ﬁ  rst 
path is altered growth factor signaling—
for example, activation of the EGFR-
Ras-mitogen activated protein kinase, 
platelet-derived growth factor, or Akt 
pathways—which, both independently 
and through pathway crosstalk, lead to 
cell proliferation, cell cycle progression, 
and apoptosis inhibition (Figure 1). The 
second path is direct dys-regulation of 
cell cycle arrest, such as p16ink4a control 
of Rb or p14arf modulation of MDM2 
and Tp53, among others. 
    Current Diagnosis and Prognosis
    At present, beyond the positive 
predictive value of increasing 
malignancy, as deﬁ  ned 
histopathologically (Table 1), survival 
of patients with GBM is predicated 
on clinical variables, including the 
patient’s age and condition (Karnofsky 
performance score) at diagnosis, 
tumor location and extent of surgical 
resection, and administration of 
adjuvant radiotherapy and/or 
chemotherapy [1–5]. With respect to 
each modality—surgery, radiation, 
or chemotherapy—the survival 
advantage for each remains modest, 
on the order of a few months, with an 
average overall survival from the time 
of initial diagnosis of about 12 months. 
Therefore, therapies that promote a 
meaningful survival advantage, while 
promoting and enhancing quality of 
life, are urgently needed.
  Targeting Tumors  with  dsRNA
    Because EGFR alterations are a 
common feature of many malignant 
tumors, including non-small-cell lung 
and colon cancers and malignant 
melanoma, among others, a variety 
of techniques have been designed to 
target the EGFR and its downstream 
agents, including antibodies, antisense 
RNAs, and a large number of small 
molecule inhibitors [7,8]. While many 
of these efforts have met with some 
success in other cancer types, none 
have had profound or lasting activity 
against GBM. Levitzki and colleagues 
have used a different strategy to target 
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cells overexpressing EGFR: they use 
synthetic, double-stranded RNAs 
(dsRNAs), linked to EGF, to obtain 
selective and efﬁ  cient killing of EGFR 
overexpressing malignant gliomas in 
vitro and in vivo in a mouse model [6]. 
    dsRNA motifs are central to immune 
regulation, and dsRNA may play several 
roles in eukaryotic cells—blocking 
tolerance to tumor-associated self- 
and foreign antigens; activation of 
RNaseL and protein kinase R, which 
effect transcriptional and translational 
inhibition while simultaneously 
spurring interferon expression; 
induction of apoptosis; activation of 
small RNA-mediated interference; 
promotion of extracellular or paracrine 
effects through secretion of interferons 
and other cytokines (a “bystander 
effect’); and release of dsRNAs from 
infected cells, thereby activating 
antigen-presenting cells [9,10].
    Given this panoply of potential 
effects, Shir et al. coupled dsRNA 
(a polyinosine-cytosine or poly IC 
construct) to EGF, and demonstrated 
that EGFR-targeted poly IC induced 
rapid and pronounced apoptosis of 
EGFR overexpressing cells, but not of 
cells expressing low EGFR, no EGFR, 
or mutated constitutively active EGFR, 
which cannot bind EGF. A variety 
of cytokines, including interferon-
α, Gro-α, and interferon-induced 
protein-10/CXCL10—all of which 
have been shown to have antitumor 
or antiproliferative activity—were 
also expressed by the tumor cells. 
Importantly, these results were 
replicated in vivo, where dsRNA 
treatment led to survival of all animals 
with intracranial tumors for greater 
than 244 days. In addition, dsRNA 
treatment was equally applicable in 
vitro and in vivo for two other EGFR 
overexpressing cell lines, A431 (a 
cervical carcinoma) and MDA-MD-468 
(a breast carcinoma), suggesting that 
this approach has potential for other 
tumor types that overexpress EGFR. 
  Clinical  Implications
    While other treatments have had 
encouraging in vitro and in vivo debuts 
in animals, they have failed when 
translated to malignant gliomas in 
humans. Only clinical data will show 
whether the approach described above 
will be successful in human patients. 
However, there is reason for cautious 
optimism: based on recent advances in 
delivery of macromolecules to the brain, 
speciﬁ  cally by convection-enhanced 
delivery, pioneered by Edward Oldﬁ  eld 
at the National Institutes of Health, it 
appears that ligand-guided delivery of 
dsRNA may hold signiﬁ  cant clinical 
promise [11,12]. Convection-enhanced 
delivery permits selective delivery of 
heterogenous macromolecules to 
targeted-diseased regions within the 
brain both safely and efﬁ  ciently, while 
minimizing or eliminating toxicities to 
the healthy brain or outside the central 
nervous system [11,12]. And since the 
system of Shir et al. can link dsRNAs to 
essentially any molecule, ligand-guided 
delivery might be broadly applicable 
to any cancer, and, quite likely, to 
benign disorders as well, so long as an 
endocytosed receptor is substantially 
overexpressed compared to normal 
cells. It appears to me that this is one 
method that should be fast-tracked to 
the clinic.   
DOI: 10.1371/journal.pmed.0030031.g001
  Figure 1.   Representative Clinical, 
Pathological, and Molecular Genetic 
Features of Glioblastoma Multiforme 
      The top panel shows an illustrative set of 
neuroimages from a patient with glioblastoma 
multiforme. On the left and in the center are 
gadolinium-enhanced T1-weighted axial 
magnetic resonance images from the day 
before and the day after resection of a large 
left frontal GBM. The patient was treated with 
postoperative radiation and chemotherapy. 
He presented again, 11 months after the ﬁ  rst 
surgery, with stupor and a contrast-enhanced 
computed tomographic scan (right), which 
showed a massive and fatal recurrence. 
    The middle panel shows histopathological 
examples of this patient’s tumor. In the left 
image, there is evidence of hypercellularity, 
pseudopalisading necrosis (small arrow), 
and vascular proliferation with hemorrhage 
(large arrow). In the center image, there is 
hypercellularity with intermittent mitotic 
ﬁ  gures (small arrows), while in the image to 
the right, there are several areas with ﬂ  orid 
endothelial proliferation (small arrows). See 
also Table 1. All ﬁ  gures are 200× magniﬁ  cation.
     The bottom panel shows a schematic of 
current models of astrocytoma development 
and progression. The de novo pathway is 
located on top, and the secondary pathway 
is located on bottom. The principal genetic 
changes are noted for each pathway. Neuronal 
tumors and oligodendrogliomas (left top 
and bottom, respectively) appear to arise 
independently. Average survivals are noted 
for each astrocytoma type. While basic genetic 
features have been elaborated, they have 
been inconsistently found in GBMs, and as 
yet appear not to be consistently effective for 
targeted therapy. There remains a great deal 
unknown about the process by which these 
tumors progress to the most malignant state, 
whether the tumor is a de novo GBM or arises 
secondarily. Unknown steps from potential 
progenitor or pluripotent tumor cell(s) are 
indicated by small arrows. 
  Table 1.   Histological Features and Prognosis in Patients with Glioma   
Tumor Features Grade II Astrocytoma Grade III Astrocytoma Grade IV Astrocytoma
Average survival 2–10 years  2–5 years  9–12 months 
Proliferation +/− ++ +++
Invasion of brain ++ ++ +++
Neoangiogenesis − − +++
Necrosis − − +++
Treatment 
responsiveness
−/+ +/++ Minimal
    +, presence of characteristic;  −, absence of characteristic. Greater numbers of + signs indicate greater prevalence of the characteristic, whereas combinations of 
+ and − indicate that the characteristic may or may not be present.
  DOI:  10.1371/journal.pmed.0030031.t001 
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